Margaret Olinger - Jul 12, 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Commercial Officer
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol
AMLX
Transactions as of
Jul 12, 2023
Transactions value $
$7,400
Form type
4
Date filed
7/14/2023, 04:20 PM
Previous filing
May 24, 2023
Next filing
Dec 29, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Options Exercise $7.4K +20K +8.65% $0.37* 251K Jul 12, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (Right to Buy) Options Exercise $0 -20K -22.33% $0.00 69.6K Jul 12, 2023 Common Stock 20K $0.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As of the date of this filing, 67,156 shares subject to the option are vested and exercisable. 2,421 shares subject to such option vest and become exercisable in substantially equal monthly installments until August 13, 2023.